About us | ISO13485 | Neptis

ORA, established in 2006, is a recognized world player in the supply of fully automated PET radiopharmaceutical synthesizers (radiochemistry modules) for use in the production of sterile injectable PET drug products.

In 2009, using extensive working knowledge and experience gained in PET manufacturing, the NEPTIS® project was launched. The synthesizers are specifically designed and constructed to meet current industry standards and user requirements with its potential future needs also in mind. The robust hardware and advanced software capabilities provide the means to create an unlimited number of individualized radiotracer synthesis applications.

Currently, there are more than 500 NEPTIS® radiopharmaceutical synthesizers in use worldwide in both academic and commercial environments.

OUR MISSION is INNOVATE, DESIGN and RELIABLY SUPPLY your BEST POSSIBLE customer EXPERIENCE.

We aim to provide optimized radiochemical applications and deliver the best possible integrated chemistry experience to meet your regulatory and operational needs as PET pharmaceutical producers and developers. With an open and flexible platform these combined challenges can be met by offering devices that are efficient and competitive in the marketplace.

Our Approach

ORA developed and implemented a Quality Management System , this is achieved through customer-focused continuous improvement and by maintaining an effective quality system that complies with regulatory requirements.

Our Marketing Authorizations

To date, since our NEPTIS® synthesizer has been selected as a manufacturing platform for Eli Lilly’s AMYVID™, more than 10 authorizations have been approved for NEPTIS® in Europe, Japan and USA. Proven experience has also led to several patented design improvements and innovations.